Orient Pharma Co., Ltd. (TPEX:4166)

Market Cap	8.24B
Revenue (ttm)	1.22B
Net Income (ttm)	107.37M
Shares Out	223.04M
EPS (ttm)	0.48
PE Ratio	76.75
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,236
Average Volume	86,728
Open	37.05
Previous Close	37.05
Day's Range	35.50 - 37.05
52-Week Range	24.85 - 50.70
Beta	-0.15
RSI	61.57
Earnings Date	Aug 13, 2025

About Orient Pharma

Orient Pharma Co., Ltd. engages in the research and development, manufacturing, and sales of drugs in Taiwan and internationally. The company develops anti-psychotics and psychostimulants, as well as drugs for treating Parkinson’s and Alzheimer’s diseases; and products for the treatment of sialorrhea, tuberculosis, and attention deficit hyperactivity disorder. It is also developing drug delivery technologies, such as multi-stages-controlled release technology, trans-dermal patches, oral disintegrating tablets, sustained release technology, and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 173
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4166

Financial Performance

In 2024, Orient Pharma's revenue was 1.22 billion, an increase of 37.41% compared to the previous year's 889.91 million. Earnings were 107.37 million, an increase of 381.76%.